ARV-6723

DRUG2 trials

Sponsors

Arvinas Operations Inc., Arvinas Inc.

Conditions

Advanced CancerAdvanced Solid Tumor

Phase 1

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

RecruitingNCT07749586

Arvinas Inc.Advanced Solid Tumor

Start: 2026-07-29End: 2032-03-31Target: 499Updated: 2026-10-13

A Phase 1/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ARV-6723 Administered as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Not yet recruitingCTIS2026-525614-57-00

Arvinas Operations Inc.Advanced Cancer

Target: 60Updated: 2026-10-22